Editorial: Nitro-fatty acids: novel drug candidates for the co-treatment of atherosclerosis and nonalcoholic fatty liver disease.
作者信息
Rom Oren, Liu Yuhao, Chang Lin, Chen Y Eugene, Aviram Michael
机构信息
Department of Internal Medicine, Frankel Cardiovascular Center, University of Michigan Medical Center, Michigan, USA.
The Lipid Research Laboratory, Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel.
出版信息
Curr Opin Lipidol. 2020 Apr;31(2):104-107. doi: 10.1097/MOL.0000000000000666.
Abstract
摘要
相似文献
1
Editorial: Nitro-fatty acids: novel drug candidates for the co-treatment of atherosclerosis and nonalcoholic fatty liver disease.社论：硝基脂肪酸：用于联合治疗动脉粥样硬化和非酒精性脂肪性肝病的新型候选药物。
Curr Opin Lipidol. 2020 Apr;31(2):104-107. doi: 10.1097/MOL.0000000000000666.
2
Non-alcoholic fatty liver disease: a metabolic burden promoting atherosclerosis.非酒精性脂肪性肝病：促进动脉粥样硬化的代谢负担。
Clin Sci (Lond). 2020 Jul 17;134(13):1775-1799. doi: 10.1042/CS20200446.
3
Replacement of Dietary Saturated Fat by PUFA-Rich Pumpkin Seed Oil Attenuates Non-Alcoholic Fatty Liver Disease and Atherosclerosis Development, with Additional Health Effects of Virgin over Refined Oil.用富含多不饱和脂肪酸的南瓜籽油替代膳食饱和脂肪可减轻非酒精性脂肪性肝病和动脉粥样硬化的发展，且原生油比精炼油具有更多健康益处。
PLoS One. 2015 Sep 25;10(9):e0139196. doi: 10.1371/journal.pone.0139196. eCollection 2015.
4
Aspirin Improves Nonalcoholic Fatty Liver Disease and Atherosclerosis through Regulation of the PPAR-AMPK-PGC-1 Pathway in Dyslipidemic Conditions.阿司匹林通过调节脂代谢紊乱条件下的 PPAR-AMPK-PGC-1 通路改善非酒精性脂肪性肝病和动脉粥样硬化。
Biomed Res Int. 2020 Mar 19;2020:7806860. doi: 10.1155/2020/7806860. eCollection 2020.
5
Biological Mechanisms and Related Natural Inhibitors of CD36 in Nonalcoholic Fatty Liver.CD36 在非酒精性脂肪肝中的生物学机制及相关天然抑制剂
Drug Des Devel Ther. 2022 Nov 4;16:3829-3845. doi: 10.2147/DDDT.S386982. eCollection 2022.
6
Use of farnesoid X receptor agonists to treat nonalcoholic fatty liver disease.使用法尼醇X受体激动剂治疗非酒精性脂肪性肝病。
Dig Dis. 2015;33(3):426-32. doi: 10.1159/000371698. Epub 2015 May 27.
7
SIRT6: therapeutic target for nonalcoholic fatty liver disease.SIRT6：非酒精性脂肪性肝病的治疗靶点。
Trends Endocrinol Metab. 2022 Dec;33(12):801-803. doi: 10.1016/j.tem.2022.10.004. Epub 2022 Nov 1.
8
Amitriptyline inhibits nonalcoholic steatohepatitis and atherosclerosis induced by high-fat diet and LPS through modulation of sphingolipid metabolism.阿米替林通过调节鞘脂代谢抑制高脂肪饮食和 LPS 诱导的非酒精性脂肪性肝炎和动脉粥样硬化。
Am J Physiol Endocrinol Metab. 2020 Feb 1;318(2):E131-E144. doi: 10.1152/ajpendo.00181.2019. Epub 2019 Dec 10.
9
In vitro treatment of HepG2 cells with saturated fatty acids reproduces mitochondrial dysfunction found in nonalcoholic steatohepatitis.用饱和脂肪酸对HepG2细胞进行体外处理，可重现非酒精性脂肪性肝炎中发现的线粒体功能障碍。
Dis Model Mech. 2015 Feb;8(2):183-91. doi: 10.1242/dmm.018234. Epub 2014 Dec 24.
10
Research advances in the relationship between nonalcoholic fatty liver disease and atherosclerosis.非酒精性脂肪性肝病与动脉粥样硬化关系的研究进展
Lipids Health Dis. 2015 Dec 3;14:158. doi: 10.1186/s12944-015-0141-z.
引用本文的文献
1
Nitro-fatty acids-mediated nitroalkylation modulates fine-tuning catalase antioxidant function during salinity stress in plants.硝基脂肪酸介导的硝基烷基化在植物盐胁迫期间调节过氧化氢酶抗氧化功能的微调。
Protein Sci. 2025 Mar;34(3):e70076. doi: 10.1002/pro.70076.
2
The interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease.非酒精性脂肪性肝病与动脉粥样硬化性心血管疾病之间的相互作用。
Front Cardiovasc Med. 2023 May 2;10:1116861. doi: 10.3389/fcvm.2023.1116861. eCollection 2023.
3
Chemoproteomic profiling reveals cellular targets of nitro-fatty acids.化学生物组学分析揭示了硝酰脂肪酸的细胞靶标。
Redox Biol. 2021 Oct;46:102126. doi: 10.1016/j.redox.2021.102126. Epub 2021 Sep 7.
本文引用的文献
1
Loss-of-function genomic variants highlight potential therapeutic targets for cardiovascular disease.功能丧失性基因组变异凸显出心血管疾病的潜在治疗靶点。
Nat Commun. 2020 Dec 18;11(1):6417. doi: 10.1038/s41467-020-20086-3.
2
Pharmacokinetic and Pharmacodynamic Effects of Oral CXA-10, a Nitro Fatty Acid, After Single and Multiple Ascending Doses in Healthy and Obese Subjects.口服 CXA-10（一种硝基脂肪酸）在健康和肥胖受试者中单次和多次递增剂量后的药代动力学和药效学效应。
Clin Transl Sci. 2019 Nov;12(6):667-676. doi: 10.1111/cts.12672. Epub 2019 Aug 12.
3
Novel gene regulatory networks identified in response to nitro-conjugated linoleic acid in human endothelial cells.新型基因调控网络在人内皮细胞对硝基共轭亚油酸的反应中被鉴定出来。
Physiol Genomics. 2019 Jun 1;51(6):224-233. doi: 10.1152/physiolgenomics.00127.2018. Epub 2019 May 10.
4
Nitro-fatty acids protect against steatosis and fibrosis during development of nonalcoholic fatty liver disease in mice.硝基脂肪酸可预防非酒精性脂肪肝疾病小鼠模型中肝脂肪变性和肝纤维化的发生。
EBioMedicine. 2019 Mar;41:62-72. doi: 10.1016/j.ebiom.2019.02.019. Epub 2019 Feb 13.
5
Electrophilic nitro-oleic acid reverses obesity-induced hepatic steatosis.亲电硝基油酸逆转肥胖诱导的肝脂肪变性。
Redox Biol. 2019 Apr;22:101132. doi: 10.1016/j.redox.2019.101132. Epub 2019 Feb 1.
6
Nitro-fatty acids are formed in response to virus infection and are potent inhibitors of STING palmitoylation and signaling.硝酰化脂肪酸是病毒感染的响应产物，强烈抑制 STING 的棕榈酰化和信号转导。
Proc Natl Acad Sci U S A. 2018 Aug 14;115(33):E7768-E7775. doi: 10.1073/pnas.1806239115. Epub 2018 Jul 30.
7
Nitro-fatty acids: New drug candidates for chronic inflammatory and fibrotic diseases.硝酰基脂肪酸：用于治疗慢性炎症和纤维化疾病的新型药物候选物。
Nitric Oxide. 2018 Sep 1;79:31-37. doi: 10.1016/j.niox.2018.06.006. Epub 2018 Jun 23.
8
The discovery of nitro-fatty acids as products of metabolic and inflammatory reactions and mediators of adaptive cell signaling.硝基脂肪酸作为代谢和炎症反应产物以及适应性细胞信号转导介质的发现。
Nitric Oxide. 2018 Jul 1;77:106-111. doi: 10.1016/j.niox.2018.05.002. Epub 2018 May 6.
9
Nitrated fatty acids in cardiovascular diseases.心血管疾病中的硝化脂肪酸
Nitric Oxide. 2018 Mar 26. doi: 10.1016/j.niox.2018.03.016.
10
Inflammatory signaling and metabolic regulation by nitro-fatty acids.硝基脂肪酸介导的炎症信号传导与代谢调控
Nitric Oxide. 2018 Mar 22. doi: 10.1016/j.niox.2018.03.017.
Zotero 插件